Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis?

Nephrology Dialysis Transplantation

Volumn 26, Issue 3, 2011, Pages 1006-1010

  Veighey, Kristin ^a   Booth, John ^a   Davenport, Andrew ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

copper; haemodialysis; phosphate binders; selenium; zinc

Indexed keywords

ALBUMIN; CALCIUM; CHOLESTEROL; COPPER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANTHANUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT; SELENIUM; SEVELAMER; TRACE ELEMENT; ZINC;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; COPPER BLOOD LEVEL; DIALYSIS; DIETARY INTAKE; FEMALE; HEMODIALYSIS; HUMAN; ION EXCHANGE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NUTRITIONAL STATUS; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; SUPPLEMENTATION; ZINC BLOOD LEVEL;

ADULT; AGED; CHELATING AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATES; POLYAMINES; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPECTROPHOTOMETRY, ATOMIC; TRACE ELEMENTS;

EID: 79952182052     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq520     Document Type: Article

References (25)

1. Prasad AS. Zinc in growth and development and spectrum of human zinc deficiency. J Am Coll Nutr 1988;7:377-384
2. Tapiero H, Townsend DM, Tew KD. Trace elements in human physiology and pathology. Copper. Biomed Pharmacother 2003;57:321-325
3. Tonelli M, Wiebe N, Hemmelgarn B et al. For the Alberta Kidney Disease Network. Trace elements in haemodialysis patients: a systematic review and meta-analysis. BMC Med 2009;7:25
4. Foote JW, Hinks LJ. Zinc absorption in haemodialysis patients. Ann Clin Biochem 1988;25:398-402
5. Batista MN, Cuppari L, de Ftima Campos Pedrosa L et al. Effect of end-stage renal disease and diabetes on zinc and copper status. Biol Trace Elem Res 2006;112:1-12 (Pubitemid 44337201)
6. Szpanowska-Wohn A, Kolarzyk E, Chowaniec E. Estimation of intake of zinc, copper and iron in the diet of patients with chronic renal failure treated by haemodialysis. Biol Trace Elem Res 2008;124:97-102
7. Lee SH, Huang JW, Hung KY et al. Trace metals' abnormalities in haemodialysis patients: relationship with medications. Artif Organs 2000;24:841-844
8. Pehlivan E, Altun T. Ion-exchange of Pb2+, Cu2+, Zn2+, Cd2+, and Ni2+ ions from aqueous solution by Lewatit CNP 80. J Hazard Mater 2007;140:299-307
9. Takagi K, Masuda K, Yamazaki M et al. Metalion and vitamin adsorption profiles of phosphate binder ion-exchange resins. Clin Nephrol 2010;73:30-35
10. Rounis E, Laing CM, Davenport A. Acute neurological presentation due to copper deficiency in a haemodialysis patient following gastric bypass surgery. Clin Nephrol 2010; In press
11. Davenport A. Low molecular weight heparin for routine haemodialy-sis. Hemodial Int 2008;12: S34-S37
12. Davenport A, Newton KE, Toothill C et al. The effect of aluminium mobilisation following successful renal Allograft transplantation on the increase in haemoglobin during the first six months after transplantation. Kidney Int 1993;43:1313-1318
13. Bellia JP, Newton KE, Davenport A et al. Silicon and aluminium and their inter-relationship in serum and urine after renal transplantation. Eur J Clin Invest 1994;24:703-710 (Pubitemid 24312528)
14. Morey B, Walker R, Davenport A. More dietetic time, better outcome? A randomized prospective study investigating the effect of more dietetic time on phosphate control in end-stage kidney failure haemodialysis patients. Nephron Clin Pract 2008;109: c173-c180
15. Davenport A, Gardner C, Delaney M. Pan Thames Renal Audit Group. The effect of dialysis modality on phosphate control: haemodialysis compared to haemodiafiltration. The Pan Thames Renal Audit. Nephrol Dial Transplant 2010;25:897-901
16. Davenport A, Gardner C, Delaney M. Pan Thames Renal Audit. Do differences in dialysis prescription impact on KDOQI bone mineral targets? The Pan Thames Renal Audit Group. Blood Purif 2010;30:111-117
17. Shantouf R, Budoff MJ, Ahmadi N et al. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in haemodialysis patients. Am J Nephrol 2008;28:275-279
18. Delmez J, Block G, Robertson J et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on haemodialysis. Clin Nephrol 2007;68:386-391 (Pubitemid 350258767)
19. Davenport A, Murcutt G, Whiting S. Cross-sectional audit of blood lead levels in regular outpatient haemodialysis patients dialysing in north London. Nephrology (Carlton) 2009;14:476-481
20. Spada PL, Rossi C, Alimonti A et al. Iron, zinc and aluminium ferritin content of hemodialysis hyperferritinemic patients: comparison with other hyperferritinemic clinical conditions and normoferritinemic blood donors. Clin Biochem 2009;42:1654-1657
21. Cole CR, Grant FK, Swaby-Ellis ED et al. Zinc and iron deficiency and their interrelations in low-income African American and Hispanic children in Atlanta. Am J Clin Nutr 2010;91:1027-1034
22. Davenport A. Intradialytic complications during hemodialysis. Haemodial Int 2006;10:162-167
23. Davenport A, Williams PS, Roberts NB et al. Sepsis: a cause of aluminum release from tissue stores associated with acute neurological dysfunction and mortality. Clin Nephrol 1988;30:48-51
24. Laclaustra M, Stranges S, Navas-Acien A et al. Serum selenium and serum lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Atherosclerosis 2010;210:643-648
25. Stranges S, Laclaustra M, Ji C et al. Higher selenium status is associated with adverse blood lipid profile in British adults. J Nutr 2010;140:81-87